OEA, a lipid that naturally occurs in the body, has been found to have a significant impact on GLP-1 levels, a hormone crucial for glucose regulation. This discovery, detailed in a recent study, highlights the potential of OEA as a natural supplement to enhance GLP-1 production, offering a promising alternative to medications that currently cause side effects such as muscle loss and digestion problems.
The study, conducted in Brisbane, Australia, involved 43 overweight and obese participants who were not diagnosed with metabolic disorders. The results showed that OEA supplementation led to a 13.6% increase in GLP-1 levels, which is approximately 20% higher than the placebo group. This effect was observed within 15 minutes of taking the OEA supplement and persisted even after participants consumed their second meal, four hours post-dose.
The researchers found that OEA binds to the GPR119 receptor in the L cells, which potentiates GLP-1 release. This mechanism is crucial for glucose regulation and may explain why OEA supplementation leads to increased GLP-1 levels. The study also revealed that OEA supplementation can help restore gut dysbiosis, a condition often associated with obesity and eating ultra-processed foods.
The implications of these findings are significant. By supplementing OEA, the body's GLP-1 production mechanism becomes more efficient and fine-tuned, potentially offering a natural solution to metabolic disorders. The study's findings also suggest that OEA could be an alternative to GLP-1 receptor agonist medications, which are known to cause side effects.
The company behind the study, Saanroo, is now exploring further applications of OEA. They plan to apply for new health benefit claims for TRPTI, including in major markets such as the US, Australia, and Canada. In Australia, the practitioner-only brand Designs for Health has already launched products containing TRPTI.
Saanroo is also planning further studies on OEA and its effects on metabolic health and health span. The company has completed a pharmacokinetic study comparing TRPTI's bioavailability and absorption with standard OEA and will also study if a lower dose of TRPTI is capable of elevating GLP-1 production in the body.
In conclusion, the study's findings highlight the potential of OEA as a natural supplement to enhance GLP-1 production, offering a promising alternative to medications that currently cause side effects. The implications of these findings are significant, and further research is needed to fully understand the potential of OEA in metabolic health and health span.
